Kyntra Bio
KYNB
143 hedge funds and large institutions have $1.2B invested in Kyntra Bio in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 56 increasing their positions, 48 reducing their positions, and 25 closing their positions.
532% more call options, than puts
Call options by funds: $34.3M | Put options by funds: $5.44M
26% more capital invested
Capital invested by funds: $950M → $1.2B (+$248M)
17% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 48
0.07% more ownership
Funds ownership: 3.12% → 3.18% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 152 → 143 (-9)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.7M |
| 2 |
Primecap Management
Pasadena,
California
|
+$11M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$8.57M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8.53M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$9.97M |
| 2 |
AC
Armistice Capital
New York
|
-$9.07M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.53M |
| 4 |
Renaissance Technologies
New York
|
-$7.5M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.68M |
KYNB Hedge Fund Activity: Q4 2022 in Review
143 of the 6,236 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2022, worth a combined $1.2B — up 26% from $950M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of KYNB and 18 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 56 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $13.7M. The largest seller was First Trust Advisors, cutting an estimated $9.97M.
- 143 institutional investors held Kyntra Bio (KYNB) as of Q4 2022, down from 152 in Q3 2022.
- Funds reported $1.2B of Kyntra Bio stock for Q4 2022, up 26% quarter-over-quarter.
- 18 funds opened new Kyntra Bio positions in Q4 2022 and 25 closed out, a net change of -7 holders.
- The largest Kyntra Bio buyer in Q4 2022 was T. Rowe Price Associates, an estimated $13.7M added.
- The largest Kyntra Bio seller in Q4 2022 was First Trust Advisors, an estimated $9.97M sold.
Based on aggregated 13F filings for Q4 2022.